Soleo Health Prepared to Meet Increased Demand of FDA-Approved LEQEMBI™ (lecanemab-irmb) to Treat Alzheimer’s Disease
In January 2023, Soleo Health was selected by Eisai Inc., a developer of pharmaceuticals, as the specialty pharmacy distribution partner for LEQEMBI to treat Alzheimer’s Disease. At that time, the highly anticipated treatment -- an anti-amyloid monoclonal antibody used to treat mild cognitive impairment (MCI) due to Alzheimer’s Disease and mild Alzheimer’s Disease (collectively known as early Alzheimer’s Disease) -- had received fast-track FDA approval initially. Today, LEQEMBI received full FDA approval.
- In January 2023, Soleo Health was selected by Eisai Inc., a developer of pharmaceuticals, as the specialty pharmacy distribution partner for LEQEMBI to treat Alzheimer’s Disease.
- At that time, the highly anticipated treatment -- an anti-amyloid monoclonal antibody used to treat mild cognitive impairment (MCI) due to Alzheimer’s Disease and mild Alzheimer’s Disease (collectively known as early Alzheimer’s Disease) -- had received fast-track FDA approval initially.
- Soleo Health’s distinctive Alzheimer’s Disease TCMC is supported through the Company’s specialty pharmacy locations nationwide with pharmacy licensure in all 50 states.
- For more information about LEQEMBI therapy and services through Soleo Health, contact the Company’s Alzheimer’s Disease TCMC at 844.960.9090 or email [email protected] .